About BAG family molecular chaperone regulator 4
BAG family molecular chaperone regulator 4 (BAG4) is a protein
from Homo sapiens identified by UniProt accession
O95429, 457 residues long.
MolForge cross-references it against 0 known binders and
74 disease associations.
Target properties
| Protein name | BAG family molecular chaperone regulator 4 |
| UniProt accession | O95429 |
| Gene | BAG4 |
| Organism | Homo sapiens |
| Length | 457 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (74)
Diseases linked to this target (Open Targets).
- cancer · score 0.58
- bone development disease · score 0.56
- breast adenocarcinoma · score 0.27
- endometrial cancer · score 0.25
- head and neck squamous cell carcinoma · score 0.17
- systolic blood pressure · score 0.13
- lymphocyte count · score 0.10
- schizophrenia · score 0.09
- urate measurement · score 0.08
- bipolar disorder · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O95429-F1 | alphafold | PREDICTED | 54.83 | — |
Amino-acid sequence (457 residues)
MSALRRSGYG PSDGPSYGRY YGPGGGDVPV HPPPPLYPLR PEPPQPPISW RVRGGGPAET TWLGEGGGGD GYYPSGGAWP EPGRAGGSHQ EQPPYPSYNS NYWNSTARSR APYPSTYPVR PELQGQSLNS YTNGAYGPTY PPGPGANTAS YSGAYYAPGY TQTSYSTEVP STYRSSGNSP TPVSRWIYPQ QDCQTEAPPL RGQVPGYPPS QNPGMTLPHY PYGDGNRSVP QSGPTVRPQE DAWASPGAYG MGGRYPWPSS APSAPPGNLY MTESTSPWPS SGSPQSPPSP PVQQPKDSSY PYSQSDQSMN RHNFPCSVHQ YESSGTVNND DSDLLDSQVQ YSAEPQLYGN ATSDHPNNQD QSSSLPEECV PSDESTPPSI KKIIHVLEKV QYLEQEVEEF VGKKTDKAYW LLEEMLTKEL LELDSVETGG QDSVRQARKE AVCKIQAILE KLEKKGL
Explore BAG family molecular chaperone regulator 4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets